Merck Halts Keytruda Qlex Supply In Six European Countries After Dutch Court Injunction
Executives called the affected markets small and said Qlex sales reached $830 million in the quarter, mostly in the U.S.
Merck, the drugmaker behind the cancer therapy Keytruda, will not supply its subcutaneous version, Keytruda Qlex, in six European countries while a Dutch court injunction stands, an executive said on the company's third-quarter earnings call Thursday. The company put Qlex sales at $830 million for the quarter and said the product's U.S. trajectory remains strong.
Six markets go dark for now
Yanni Oosthuizen, president of Merck's Oncology Business Unit and MSD International, said on the call that Merck
Merck's case: the ruling is not the merits
Asked by a Bernstein analyst whether the European setback was definitive and whether it posed any risk in the U.S., Chairman and CEO Rob Davis said Merck believes it holds intellectual property that gives it freedom to operate on Qlex. He said the company took action against others in the field for that reason.
"Nothing has changed to our confidence," Davis said. The injunction, he said, runs only until the hearing is held and does not speak to the merits.
Oosthuizen said Merck's longer-running IP means that, if the decision is reversed, it would have time to bring the formulation to patients in those markets.
U.S. adoption and unaffected markets
Oosthuizen said Qlex has followed a very positive path in the U.S. since Merck received a permanent J code, the billing code, on April 1. The company's objective is 30% to 40% U.S. adoption by the end of 2027.
Outside the six countries, he said Merck can supply high-adoption markets including the UK, Canada and Austria, and already sees high adoption in the UK. Launches in Canada, Japan and China are awaited, and he said Japan and China pose no supply or launch issue.
CFO Caroline Litchfield said the Keytruda family, including Keytruda and Qlex, rose 6% to $8.6 billion in the quarter, excluding currency effects. Total revenue was $18.1 billion, up 5%. Merck, which sells prescription medicines, vaccines and animal health products, narrowed its 2026 revenue guidance to $66.8 billion to $67.3 billion and raised the midpoint.
The next marker is the Dutch hearing, which Davis said the injunction lasts until.
Sources
- Merck stock rises as Q3 earnings beat estimates, 2026 outlook raised (MRK:NYSE) | Seeking Alpha — seekingalpha.com
- Merck (MRK) earnings Q3 2026 — CNBC
- Merck Tops Third-Quarter Estimates as Keytruda, Gardasil Outperform — Reuters
- Merck Stock: Earnings Beat, But Can Shares Outplay The Cancer Vaccine News? | Investor's Business Daily — investors.com
- Merck & Co., Inc., Rahway, N.J., USA Announces Third-Quarter 2026 Financial Results; Highlights Multiple Milestones Advancing Broad, Diverse Pipeline – Company Announcement - FT.com — Financial Times